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1.The Disease: Muckle Wells Syndrome (MWS) 
 
 MWS is included in a group of inflammatory diseases called Criopirin 
Associated Periodic Syndrome (CAPS), at the same time, CAPS are included in 
a bigger group , Hereditary Systemic Autoinflammatory Diseases (HSAD). All 
of the syndromes included in CAPS, are associated with mutations in CIAS1 
gene , which encodes the protein criopirin. 
 MWS  is a rare disease (1:1.000.00) that has a high autoinflammatory 
component. Its inheritance is autosomical dominant. MWS patients show a 
chronic and systemic inflammation without reason for develop it (no 
infection, no neoplasic procedure…).   
2. Targets 
• Learn what is the origin of MWS 
 
• What is the molecular 
 mechanism  of the disease 
 
• What are the current 
 treatments 
 
•What are the worst symptom 
 
3. Molecular Mechanism 
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    CIAS1 mutations cause a bigger gene expression 
Criopirin levels increase in response at the bigger 
expression 
     IL-1 levels increase because criopirin turn on 
 caspase-1, that cuts the IL-1 and makes it active 
 
     IL-1 intermediate the inflammatory response by 
 macrophages and monocytes and it is   
 increased  systemically  
 
4. Symptoms 
Skin Rashes, Pain in the joints, Hearing loss, Fever, Headache, 
Conjunctivitis, Muscle pain, Proteinuria and   Potential AA 
Amiloidosis (25%) 
 
 
 
 
 
 
 
5. Treatements 
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